title: The 'Omics' of Amyotrophic Lateral Sclerosis.
abstract: Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease that primarily affects motor neurons and is accompanied by sustained unregulated immune responses, but without clear indications of the ultimate causative mechanisms. The identification of a diverse array of ALS phenotypes, a series of recently discovered mutations, and the links between ALS and frontotemporal degeneration have significantly increased our knowledge of the disease. In this review we discuss the main features involved in ALS pathophysiology in the context of recent advances in 'omics' approaches, including genomics, proteomics, and others. We emphasize the pressing need to combine clinical imaging with various different parameters taken from omics fields to facilitate early, accurate diagnosis and rational drug design in the treatment of ALS.
authors.affiliation: Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Spanish National Research Council (CSIC)-Universidad Pablo de Olavide, University of Seville, Seville, Spain.
authors.forename: Diana
authors.initials: D
authors.lastname: Caballero-Hernandez
authors.affiliation: Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Spanish National Research Council (CSIC)-Universidad Pablo de Olavide, University of Seville, Seville, Spain; Amarna Therapeutics, Leiden, The Netherlands.
authors.forename: Miguel G
authors.initials: MG
authors.lastname: Toscano
authors.affiliation: Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Spanish National Research Council (CSIC)-Universidad Pablo de Olavide, University of Seville, Seville, Spain; Department of Medical Biochemistry, Molecular Biology, and Immunology, University of Seville Medical School, Seville, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Cejudo-Guillen
authors.affiliation: Andalusian Center for Nanomedicine and Biotechnology (BIONAND), University of Malaga, Spain.
authors.forename: Maria L
authors.initials: ML
authors.lastname: Garcia-Martin
authors.affiliation: Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Spanish National Research Council (CSIC)-Universidad Pablo de Olavide, University of Seville, Seville, Spain; Department of Medical Biochemistry, Molecular Biology, and Immunology, University of Seville Medical School, Seville, Spain.
authors.forename: Soledad
authors.initials: S
authors.lastname: Lopez
authors.affiliation: Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Spanish National Research Council (CSIC)-Universidad Pablo de Olavide, University of Seville, Seville, Spain; Department of Medical Biochemistry, Molecular Biology, and Immunology, University of Seville Medical School, Seville, Spain.
authors.forename: Jaime M
authors.initials: JM
authors.lastname: Franco
authors.affiliation: Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Quintana
authors.affiliation: Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Spanish National Research Council (CSIC)-Universidad Pablo de Olavide, University of Seville, Seville, Spain.
authors.forename: Cintia
authors.initials: C
authors.lastname: Roodveldt
authors.affiliation: Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Spanish National Research Council (CSIC)-Universidad Pablo de Olavide, University of Seville, Seville, Spain; Department of Medical Biochemistry, Molecular Biology, and Immunology, University of Seville Medical School, Seville, Spain. Electronic address: david.pozo@cabimer.es.
authors.forename: David
authors.initials: D
authors.lastname: Pozo
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000503:physiopathology* / Q000628:therapy; D005260:Female; D023281:Genomics; D006801:Humans; D008297:Male; D057285:Precision Medicine; D040901:Proteomics
keywords: amyotrophic lateral sclerosis (ALS); drug development; genomics; motor neuron diseases; neurodegeneration